01-27-2023, 10:41 PM
|
|
Banned
Join Date: Aug 2022
Location: 100% ineffective and dangerous
Posts: 587
|
|
Quote:
Career
In the late 1980s, while a graduate student researcher at the Salk Institute for Biological Studies in San Diego, California, Malone conducted studies on messenger ribonucleic acid (mRNA) technology, discovering in what Nature has described as a landmark experiment that it was possible to transfer mRNA protected by a liposome into cultured cells to signal the information needed for the production of proteins.[3][13][4] With Philip Felgner, he performed experiments on the transfection of RNA into human, rat, mouse, Xenopus, and Drosophila cells, work which was published in 1989.[3][14] In 1990, he contributed to a paper with Jon A. Wolff, Dennis A. Carson, and others, which first suggested the possibility of synthesizing mRNA in a laboratory to trigger the production of a desired protein.[15] These studies are recognized as among the earliest steps towards mRNA vaccine development.[3][16][17][18]
While Malone promotes himself as an inventor of mRNA vaccines,[1][7] credit for the distinction is more often given to the lead authors on the major papers he contributed to (such as Felgner and Wolff), later advances by Katalin Karikó and Drew Weissman,[3][19] or Moderna co-founder Derrick Rossi.[13] Ultimately, mRNA vaccines were the decades-long result of the contributions of hundreds of researchers, including Malone.[3][20] In April 2022, Davey Alba, writing for The New York Times, said that "[w]hile he was involved in some early research into the technology, his role in its creation was minimal at best", citing "half a dozen Covid experts and researchers, including three who worked closely with Dr. Malone."[7]
Malone has served as director of clinical affairs for Avancer Group, assistant professor at the University of Maryland School of Medicine, and an adjunct associate professor of biotechnology at Kennesaw State University.[21] He was CEO and co-founder of Atheric Pharmaceutical,[22] which in 2016 was contracted by the U.S. Army Medical Research Institute of Infectious Diseases to assist in the development of a treatment for the Zika virus by evaluating the efficacy of existing drugs.[23][24][25][26] Until 2020, Malone was chief medical officer at Alchem Laboratories, a Florida pharmaceutical company.[27] He has claimed he helped secure early-stage approval for research by Merck & Co. on an Ebola vaccine, in the mid-2010s.[7]
|
|
|
|
|
Linear Mode
